Английская Википедия:Fevipiprant

Материал из Онлайн справочника
Перейти к навигацииПерейти к поиску

Шаблон:Short description Шаблон:Drugbox

Fevipiprant (INN; code name QAW039) is a drug of the piprant class that was being developed by Novartis. It is a selective, orally available antagonist of the prostaglandin D2 receptor 2 (DP2 or CRTh2).[1][2][3]

By 2016 it had advanced to phase III[4] clinical trials for the treatment of asthma.[5] However, in 2019 Novartis announced that it was removing fevipiprant from its development program, given that the medicine has failed in two clinical trials in patients with moderate-to-severe asthma. The firm said that it had hoped fevipiprant would be a billion-dollar-selling asthma drug.[6]

See also

References

Шаблон:Reflist

Шаблон:Asthma and copd rx Шаблон:Prostanoidergics


Шаблон:Respiratory-system-drug-stub

  1. Ошибка цитирования Неверный тег <ref>; для сносок pmid27310331 не указан текст
  2. Шаблон:Cite journal
  3. Шаблон:Cite journal
  4. Шаблон:Cite web
  5. Шаблон:Cite journal
  6. Шаблон:Cite news